

# Biosimilars: Market Research Report

<https://marketpublishers.com/r/B80B04AC43BEN.html>

Date: April 2010

Pages: 390

Price: US\$ 3,950.00 (Single User License)

ID: B80B04AC43BEN

## Abstracts

This report analyzes the worldwide markets for Biosimilars in US\$ Million.

The report provides separate comprehensive analytics for US, Europe, and Japan.

Annual estimates and forecasts are provided for each region for the period 2008 through 2015.

The report profiles 56 companies including many key and niche players such as Biocon Ltd, Biopartners GMBH, Cipla Ltd., Dr. Reddy's Laboratories Ltd., Hospira, Inc., Intas Biopharmaceuticals Ltd., Sandoz International GmbH, Ratiopharm GmbH, Shantha Biotechnics Ltd., Teva Pharmaceutical Industries Ltd., and Wockhardt Ltd.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

## Contents

### **I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS**

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

### **II. EXECUTIVE SUMMARY**

#### **1. MARKET OVERVIEW**

Biosimilars – The New Pharma Industry’s Dynamite

European Union Ahead of the US

Regulatory Framework Approval for Biosimilars in Major Markets

Biosimilars Availability in Regional Markets

Myriad Factors Foretell Lower Market Penetration of Biosimilar Products

Issues Put Aside, Biosimilars Offer Great Promise

Growth Drivers

Patent Expiries

Patent Expiries of Select Biopharmaceuticals in Europe and United States

Patent Expiries of Major Biotechnology Products before 2007

Cost Containment Measures

An Aging Population

Presence of Major Players

Growth Restraints

Uncertain Regulations

High Lead-time

High Manufacturing Costs

Delivery and Commercialization

Automatic Substitution

Others

#### **2. MARKET PARTICIPANTS**

Market Players with Approved and Pipeline Biosimilar Drugs

### 3.GLOBAL MARKET OVERVIEW

Pharmaceutical Companies Eye Biosimilars Opportunities  
Small and New Biosimilar-Focused Companies to Gain Foothold  
Indian Companies to Emerge Strong  
Impact of Chinese Companies  
Entry Barriers for Biogenerics  
Comparison of Entry Barriers for Biogenerics in Select Global Markets  
Alternative Method of Entry  
Biosimilars Market to Remain Competitive  
Increasing Competition Between Pharma Giants and Generic Manufacturers  
Defensive Strategies for Branded Drug Manufacturers  
Companies Eye Human Insulin Biosimilars  
Insulin Manufacturers Planning to Enter European and US Biosimilars Markets  
Impediments to Market Acceptance  
Strategies to Aid Survival of Companies in Biosimilars Market

### 4.CURRENT MARKET SCENARIO AND PROSPECTS

Outlook  
Opportunities Abound for Biosimilars

### 5.GLOBAL BIOLOGICS MARKET

**Table 1.** Global Biologics Market by Region: Percentage Share Breakdown for North America, Europe, Japan, Asia-Pacific and Latin America for 2003 and 2007 (includes corresponding Graph/Chart)

Increasing Proportion of Biologics to Drive Biosimilars Market  
Biologics' Foothold in the Top 10 Pharmaceutical Drugs Worldwide: 2008  
Biologics to Strengthen Presence in the Global Pharmaceutical Market: 2015

**Table 2.** Leading Players in the Global Biologics Market: 2007 (includes corresponding Graph/Chart)

Cost Effective Methods of Pure Biologics Production

## **6.PRODUCT OVERVIEW**

Introduction

Characteristics of Biosimilars

Biological Drugs

Biological Drugs Manufacturing Process

Development Cycle of Biosimilars

Industry Participants

Classification of Pharmaceutical Companies Based on their Existing Capabilities in Global Biosimilars Market

## **7.PRODUCT APPROVALS**

Sandoz Obtains FDA Approval for Omnitrope® Pen 10 with Liquid Cartridge

Sandoz Launches Somatropin in Japan

Sandoz Obtains European Approval for Third Biosimilar, Filgrastim

Ratiopharm Introduces Neupogen Biosimilar in French Market

Biocon Launches Basalog in India

Reliance Life Sciences to Launch Three More Biosimilars in 2010

Teva Pharmaceutical Obtains Marketing Authorization from EU for TevaGrastim®

Ratiopharm Obtains Approval from EMEA for Biosimilar Ratiograstim

Hospira Introduces Retacrit in UK

Retacrit® Demonstrates Safety and Efficacy in Chemotherapy Induced Anaemia

Sandoz Collaborates with Gambro for Binocrit

ABRPL to Launch Eight Biosimilars in India

Sandoz Receives EC Approval to Introduce Epoetin Alfa Biosimilar

Sandoz Bags EC Marketing Approval for Omnitrope

Biopartners Bags EU Marketing Approval for Valtropin

Omnitrope Receives US FDA Approval

## **8.CORPORATE INITIATIVES IN THE GLOBAL BIOSIMILARS SPACE**

Innogene Kalbiotech Signs Deal with CIMAB

Hospira Acquires Global Rights to Filgrastim

Avesthagen to Start Clinical Trials of Biosimilar Darbepoetin Alfa

Cipla Joint Ventures with Chinese Firm to form Biomab

Merck & Co. Signs Deal with Insmed to Acquire Biosimilars Portfolio

Mylan Signs Partnership Deal with Biocon

Elona Biotechnologies Sets Up Two Subsidiaries

Lonza and Teva's Joint Venture Receives Approval by European Commission  
GTC Biotherapeutics Signs Collaboration with AgResearch for Biosimilars  
Apotex Signs Agreement with IBPL  
Cipla Terminates Marketing Agreement with Avesthagen  
Intas Biopharmaceuticals and Kwizda Pharma Conclude Phase I Clinical Trial of Neukine®  
Q Chip to Develop Biosimilars Based on Bioencapsulation Technology  
Hospira Signs Agreement with Celltrion to Develop Biosimilars  
Teva to Seek Approval of US Authorities  
Nomad Bioscience Signs Agreement with Bayer Innovation and Icon Genetics  
Biocon Signs Agreement with AxiCorp  
Merck Forms New Biotechnology Division, BioVentures  
Teva Pharmaceuticals Acquires CoGenesys  
Biocon and Abraxis BioScience Ink Licensing Agreement

## 9.FOCUS ON SELECT MARKET PLAYERS

Biocon Ltd. (India)  
Biopartners GMBH (Switzerland)  
Cipla Ltd. (India)  
Dr. Reddy's Laboratories Ltd. (India)  
Hospira, Inc. (US)  
Intas Biopharmaceuticals Ltd. (India)  
Sandoz International GmbH (Germany)  
Ratiopharm GmbH (Germany)  
Shantha Biotechnics Ltd. (India)  
Teva Pharmaceutical Industries Ltd. (Israel)  
Wockhardt Ltd. (India)

## 10.MARKET ANALYTICS

**Table 3.** US, Europe, and Japan Recent Past, Current, and Future Analysis for Biosimilars Market by Region: Annual Sales in US\$ Million for Years 2008 through 2015 (includes corresponding Graph/Chart)

**Table 4.** US, Europe, and Japan Recent Past, Current, and Future Analysis for Biosimilars Market by Drug Class: Annual Sales in US\$ Million for Years 2008 through 2015 for Epoetin Alpha, Granulocyte-CSF, Human Growth Hormone, Interferon, and

Insulin (includes corresponding Graph/Chart)

**Table 5.** US, Europe, and Japan Biosimilars Market by Drug Class: Percentage Share Breakdown for Years 2009, 2012, and 2015 for Epoetin Alpha, Granulocyte-CSF, Human Growth Hormone, Interferon, and Insulin (includes corresponding Graph/Chart)

### **III. MARKET**

#### **1.THE UNITED STATES**

##### **A. MARKET ANALYSIS**

Current & Future Analysis

Market Overview

Biosimilars Regulatory Pathway

Overview of Two Competing Bills Presently with the US Senate/Congress

Generics and Biologics Regulatory Pathway

US Share to Increase in the Global Biosimilars Market

Biopharma Patent Expiries to Drive Biosimilars Growth

Patent Expiries of Select Biological Products in the US

Product Approvals

##### **B. MARKET ANALYTICS**

**Table 6.** US Recent Past, Current & Future Analysis for Biosimilars – Annual Sales Figures in US\$ Million for Years 2008 through 2015 (includes corresponding Graph/Chart)

#### **2.JAPAN**

##### **A. MARKET ANALYSIS**

Current & Future Analysis

Product Approval

##### **B. MARKET ANALYTICS**

**Table 7.** Japanese Recent Past, Current & Future Analysis for Biosimilars – Annual Sales Figures in US\$ Million for Years 2008 through 2015 (includes corresponding Graph/Chart)

### **3.EUROPE**

#### **A. MARKET ANALYSIS**

Current & Future Analysis

Market Overview

Biosimilar Approvals and Filings in Europe

Biosimilars Regulatory Framework

Biosimilar Regulatory Timeline from Legislation to Approval in the EU

Growth Drivers

Payers Eye Biosimilars to Curtail Costs

Challenges Ahead

Heavy Investment and Regulations

Complex Production Process

Biocapacity

Regional Issues

Select Product Approvals

#### **B. MARKET ANALYTICS**

**Table 8.** European Recent Past, Current & Future Analysis for Biosimilars by Geographic Region – France, Germany, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2008 through 2015 (includes corresponding Graph/Chart)

**Table 9.** European 8-Year Perspective for Biosimilars by Geographic Region –Percentage Breakdown of Dollar Sales for France, Germany, UK, Spain and Rest of Europe Markets for 2009, 2012 & 2015 (includes corresponding Graph/Chart)

### **3A.FRANCE**

Market Analysis

**Table 10.** French Recent Past, Current & Future Analysis for Biosimilars – Annual Sales Figures in US\$ Million for Years 2008 through 2015 (includes corresponding Graph/Chart)

### **3B.GERMANY**

Market Analysis

**Table 11.** German Recent Past, Current & Future Analysis for Biosimilars – Annual Sales Figures in US\$ Million for Years 2008 through 2015 (includes corresponding Graph/Chart)

### **3C.THE UNITED KINGDOM**

Market Analysis

**Table 12.** UK Recent Past, Current & Future Analysis for Biosimilars – Annual Sales Figures in US\$ Million for Years 2008 through 2015 (includes corresponding Graph/Chart)

### **3D.SPAIN**

Market Analysis

**Table 13.** Spanish Recent Past, Current & Future Analysis for Biosimilars – Annual Sales Figures in US\$ Million for Years 2008 through 2015 (includes corresponding Graph/Chart)

### **3E.REST OF EUROPE**

Market Analysis

**Table 14.** Rest of Europe Recent Past, Current & Future Analysis for Biosimilars – Annual Sales Figures in US\$ Million for Years 2008 through 2015 (includes corresponding Graph/Chart)



## 4.INDIA

Indian Biopharmaceutical Industry Makes Rapid Progress

Indian Pharma Companies Explore Biosimilars Potential

Select Major Indian Companies' Marketed and Pipeline Biosimilars

Indian Firms Eyeing European Market

Select Leading Indian Companies Planning to Enter European Market

Indian Biogeneric Drugs to Enter the US Market

Product Approvals

## IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 56 (including Divisions/Subsidiaries - 62)

Region/CountryPlayers

The United States12

Canada

Europe

France

Germany

The United Kingdom

Rest of Europe

Asia-Pacific (Excluding Japan)

Latin America

Africa

Middle-East

## I would like to order

Product name: Biosimilars: Market Research Report

Product link: <https://marketpublishers.com/r/B80B04AC43BEN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B80B04AC43BEN.html>